Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Aldesleukin (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 06 Sep 2005 New trial record.